JY
PRLD icon

Jeff Yass’s Prelude Therapeutics PRLD Stock Holding History

Jeff Yass’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-267,788
Closed -$1.17M – 14283
2026
Q1 		$916K Buy
267,788
+131,879
+97% +$346K ﹤0.01% 8110
2025
Q4 		$394K Buy
+135,909
New +$229K ﹤0.01% 9327
2025
Q3 		– Sell
-39,977
Closed -$32.4K – 13586
2025
Q2 		$32.4K Sell
39,977
-37,893
-49% -$32.8K ﹤0.01% 12232
2025
Q1 		$59.8K Buy
77,870
+5,071
+7% +$4.73K ﹤0.01% 11798
2024
Q4 		$92.8K Buy
+72,799
New +$96.6K ﹤0.01% 11394
2023
Q2 		– Sell
-129,680
Closed -$739K – 12903
2023
Q1 		$739K Buy
129,680
+36,390
+39% +$222K ﹤0.01% 7593
2022
Q4 		$563K Buy
93,290
+79,699
+586% +$511K ﹤0.01% 7546
2022
Q3 		$90K Sell
13,591
-15,837
-54% -$107K ﹤0.01% 11789
2022
Q2 		$154K Buy
+29,428
New +$150K ﹤0.01% 10994
2022
Q1 		– Sell
-29,275
Closed -$268K – 13762
2021
Q4 		$364K Buy
29,275
+9,645
+49% +$157K ﹤0.01% 10017
2021
Q3 		$613K Buy
19,630
+2,477
+14% +$80.2K ﹤0.01% 8862
2021
Q2 		$491K Buy
+17,153
New +$611K ﹤0.01% 9641

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Jeff Yass's PRLD Position: Q2 2026 in Review

Jeff Yass sold out of Prelude Therapeutics (PRLD) in Q2 2026, closing a stake of 267,788 shares — an estimated $1.17M sold.

Jeff Yass first reported a position in PRLD in Q2 2021 and held it in 12 quarters. The position peaked at $916K in Q1 2026. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Jeff Yass reported no remaining Prelude Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 267,788 Prelude Therapeutics shares in Q2 2026, an estimated $1.17M.
  • Jeff Yass first reported a position in Prelude Therapeutics in Q2 2021 and held it in 12 quarters.
  • Jeff Yass's Prelude Therapeutics position peaked at $916K in Q1 2026.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.